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Background: The peak width of skeletonized mean diffusivity (PSMD) has been
proposed as a fully automated imaging marker of relevance to cerebral small vessel
disease (SVD). We assessed PSMD in relation to conventional SVD markers, global
measures of neurodegeneration, and cognition.
Methods: 145 participants underwent 3T brain MRI and cognitive assessment.
112 were patients with mild cognitive impairment, Alzheimer’s disease, progressive
supranuclear palsy, dementia with Lewy bodies, or frontotemporal dementia. PSMD,
SVD burden [white matter hyperintensities (WMH), enlarged perivascular spaces (EPVS),
microbleeds, lacunes], average mean diffusivity (MD), gray matter (GM), white matter
(WM), and total intracranial volume were quantified. Robust linear regression was
conducted to examine associations between variables. Dominance analysis assessed
the relative importance of markers in predicting various outcomes. Regional analyses
examined spatial overlap between PSMD and WMH.
Results: PSMD was associated with global and regional SVD measures, especially
WMH and microbleeds. Dominance analysis demonstrated that among SVD markers,
WMH was the strongest predictor of PSMD. Furthermore, PSMD was more closely
associated to WMH than with GM and WM volumes. PSMD was associated with WMH
across all regions, and correlations were not significantly stronger in corresponding
regions (e.g., frontal PSMD and frontal WMH) compared to non-corresponding regions.
PSMD outperformed all four conventional SVD markers and MD in predicting cognition,
but was comparable to GM and WM volumes.
Discussion: PSMD was robustly associated with established SVD markers. This new
measure appears to be a marker of diffuse brain injury, largely due to vascular pathology,
and may be a useful and convenient metric of overall cerebrovascular burden.
Keywords: small vessel disease, magnetic resonance imaging, diffusion tensor imaging, white matter
hyperintensities, cognition, dementia
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INTRODUCTION
The clinical significance of cerebral small vessel disease (SVD)
in cognitive impairment, dementia, and stroke creates an urgent
need to identify and develop valid markers of relevance to SVD
(Pantoni, 2010). Due to difficulties in detecting perturbations
to the small vessels of the brain, SVD is traditionally measured
via parenchymal alterations visible on magnetic resonance
imaging (MRI). Specifically, four core MRI features have
been identified as markers of SVD (Huijts et al., 2013;
Wardlaw et al., 2013a,b; Staals et al., 2014, 2015), namely
white matter hyperintensities (WMHs), enlarged perivascular
spaces (EPVS), microbleeds, and lacunes. Although widely
accepted as markers of SVD, lesions like WMH can have
mixed etiologies linked to inflammation, Wallerian degeneration,
and degenerative (tau) pathology (McAleese et al., 2015, 2017;
Low et al., 2019).
However, due to the generally weak associations of these
SVD markers with clinical features such as cognitive impairment
(Nitkunan et al., 2008; Patel and Markus, 2011; van der Holst
et al., 2017), coupled with the labor-intensity of quantifying these
markers, there is a need to identify and validate proxy markers of
SVD that can be applied to very large studies.
Diffusion tensor imaging (DTI) has been increasingly
suggested as a potential marker of cerebrovascular damage,
given its sensitivity to microstructural alterations (Croall et al.,
2017). Recently, a new fully automated measure, known as
the peak width of skeletonized mean diffusivity (PSMD), has
been proposed as a marker of SVD (Baykara et al., 2016).
PSMD is a DTI-derived measure based on skeletonization and
histogram analysis and is calculated as the difference between
the 95th and 5th percentile of mean diffusivity (MD) values
within the masked MD skeleton. The use of skeletonized
maps of MD eliminates contamination from cerebrospinal fluid
(CSF), and the histogram-based approach enhances the ability
to characterize subtle, diffuse diseases in the brain, such as
SVD. Promising results have emerged since its introduction.
Importantly, PSMD outperformed established MD parameters
in terms of association with processing speed, including mean,
median, peak height, full width at half maximum (Baykara et al.,
2016). On top of processing speed (Baykara et al., 2016; Deary
et al., 2018), PSMD is also strongly related to global cognition
and executive functions (Wei et al., 2019). Furthermore, PSMD
has been shown to be closely associated with higher WMH
lesion load (Wei et al., 2019), and was higher in patients with
multiple sclerosis and CADASIL compared to healthy adults
(Vinciguerra et al., 2019).
To further assess PSMD as a possible marker of SVD,
our first broad aim was to examine its relevance to vascular
pathology by investigating (1) its association with each of the
four established markers of SVD (WMH, EPVS, microbleeds,
lacunes), (2) whether it was more strongly influenced by vascular
markers compared to markers of general neurodegeneration, and
(3) the spatial overlap of PSMD and WMH severity. The second
broad aim of our study was to establish the clinical relevance
of PSMD by examining (1) the relationship between PSMD and
cognition, and (2) the relative importance of PSMD to cognition,
compared to traditional SVD markers. We hypothesized that
PSMD would be significantly related to the four markers of SVD
and cognition. Topographically, we expected that regions with
greater WMH would reflect heightened PSMD scores.
MATERIALS AND METHODS
A total of 145 participants were recruited as part of the
Neuroinflammation in Memory and Related Other Disorders
(NIMROD) study, a multimodal cohort study comprising of
older adults with varying degrees of cognitive impairment and
dementia subtypes (Bevan-Jones et al., 2017). Briefly, cognitively
impaired participants were recruited through memory clinics
in and around Cambridgeshire, or via the Dementias and
Neurodegeneration specialty of the Clinical Research Network
(DeNDRoN), the Join Dementia Research (JDR) platform1,
while cognitively healthy participants were recruited from
DeNDRON, JDR, and among friends, partners, and spouses
of patients. Participants with major psychiatric disorders, MRI
contraindications, claustrophobia, previous head injury, or
systemic inflammatory disease were excluded from the study.
A majority of participants had some degree of cognitive
impairment (n = 112), including mild cognitive impairment
(n = 20), Alzheimer’s disease (n = 16), progressive supranuclear
palsy (n = 23), dementia with Lewy bodies (n = 26), late life
depression (n = 6), and frontotemporal dementia (n = 21) (for
diagnostic criteria, see Bevan-Jones et al., 2017). The remainder
(n = 33) were cognitively healthy, i.e., Mini-Mental State
Examination (MMSE) > 26, with an absence of regular memory
symptoms, symptoms suggestive of dementia, or unstable or
significant medical illness. Participants underwent clinical and
cognitive assessments, and MRI scans. Cognition was assessed
using the MMSE and Addenbrooke’s Cognitive Examination-
Revised (ACE-R). Detailed procedures have been previously
described (Bevan-Jones et al., 2017).
Image Acquisition
Participants underwent MRI scanning at the Wolfson Brain
Imaging Centre (WBIC) on a Siemens 3T Tim Trio or
Verio (Siemens Healthcare, Erlangen, Germany). Three-
dimensional T1-weighted sequences [176 slices, 1.0-mm
thickness, repetition time (TR) = 2300 ms, echo time
(TE) = 2.98 ms, field of view = 256 × 240 mm2, flip
angle = 9◦, voxel size = 1 × 1 × 1mm3], T2 fluid attenuated
inversion recovery (FLAIR) images (75 slices, 2.0 mm
thickness, TR = 12,540 ms, TE = 132 ms, flip angle = 120◦),
susceptibility-weighted imaging (SWI) (40 slices, 2.0 mm
thickness, TR = 35 ms, TE = 20 ms, flip angle = 17◦, acquisition
matrix 256 × 240; voxel size = 1 × 1 × 2mm3), and diffusion-
weighted imaging (63 slices, 2.0 mm thickness, 63 diffusion
directions, TR = 11,700 ms, TE = 106 ms, b-value 1 = 0 s/mm2,
b-value 2 = 1000 s/mm2, acquisition matrix 96 × 96; voxel
size = 2× 2× 2mm3) were obtained.
1https://www.joindementiaresearch.nihr.ac.uk
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Peak Width of Skeletonized Mean
Diffusivity
Peak width of skeletonized mean diffusivity was computed
automatically using a modified version of the automated
procedure described by Baykara et al. (2016). The shell script
is freely available online2. However, instead of performing eddy
current corrections using the default eddy_correct tool, we
modified the script to use the eddy tool which performs outlier
replacement in areas of partial or complete signal dropout.
Brain masks were created with Brain Extraction Tool (BET) in
FSL3 (FMRIB, Oxford, United Kingdom), and diffusion tensor
and scalar diffusion parameters were estimated using DTIFIT.
Computation of PSMD involved two steps: (1) the skeletonization
of MD data and (2) histogram analysis. The Tract-based Spatial
Statistics (TBSS) pipeline on FSL was used to skeletonize DTI
data, i.e., creating a common white matter (WM) skeleton,
starting by registering all fractional anisotropy (FA) volumes
to standard space using the non-linear registration tool FNIRT
and the standard space FMRIB 1 mm FA template. A WM
skeleton is then created from registered FA volumes at a threshold
FA value of 0.2, and MD volumes are projected onto the FA
skeleton. This MD skeleton is further masked with a template
skeleton thresholded at an FA value of 0.2 to avoid CSF
2http://www.psmd-marker.com
3http://fsl.fmrib.ox.ac.uk/fsl
contamination. Using histogram analysis, PSMD is calculated as
the difference between the 95th and 5th percentile of the voxel-
based MD values within the masked MD skeleton (Figure 1).
Mean and standard deviations of FA and MD were also obtained
from the same skeletonized maps in FSL. All study samples
were processed using the same pipeline, template skeleton, and
mask. Quality assessment was conducted using the eddy_quad
tool in FSL, and through visual inspection of all images. To
examine regional associations, we further computed region-
specific PSMD values. In order to compare regional PSMD
directly with regional WMH volumes, we extracted lobar regions
from skeletonized MD images by applying the same lobar mask
used in WMH segmentation registered to the same standard
space, and conducted separate histogram analyses on each region
to extract PSMD values from each lobe.
Head motion of each subject was obtained using eddy_quad
on FSL. To account for individual differences in head movement
contributing to diffusion indices, head motion was included as a
covariate in all analyses involving PSMD.
Quantification of SVD
Semi-Quantitative Measurements
White matter hyperintensities were rated visually by experienced
raters, blinded to all clinical information on FLAIR images
according to the Fazekas scale (Fazekas et al., 1987). Within each
hemisphere, periventricular (PVH) and deep WMH (DWMH)
FIGURE 1 | Illustration of (A) white matter hyperintensity load on MRI, (B) skeletonized mean diffusivity maps, and (C) histogram analysis used to obtain PSMD
value. Two study participants are compared – one with low SVD burden (Top) and one with high SVD burden (Bottom).
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were rated separately on the following scale: PVH (0 = absent;
1 = “caps” or pencil-thin lining; 2 = smooth “halo”; 3 = irregular
PVH signal extending into the deep WM), DWMH (0 = absent;
1 = punctate foci; 2 = beginning confluence; 3 = large confluent
areas). All scans were manually rated by a single rater (AL),
and a randomly selected subset of one-third was rated by a
second rater (JS) for reliability testing. The intra-class correlation
coefficient (ICC) was 0.85. Twenty percent of all scans were
randomly selected and re-rated by the first rater (AL) to assess
intra-rater reliability (ICC 0.89). EPVS were rated on T2-
weighted images using a validated visual rating scale (Potter
et al., 2015). EPVS were rated separately in the basal ganglia
(BG), centrum semiovale (CSO), and midbrain, as EPVS in
different regions have been suggested to have different underlying
pathologies. As per the validated scale, EPVS-BG and EPVS-
CSO were rated on a 5-point scale ranging from 0 to 4,
accordingly: 0 (none), 1 (1–10), 2 (11–20), 3 (21–40), and 4
(>40). EPVS in the midbrain were rated dichotomously based
on the presence or absence of EPVS. Cerebral microbleeds were
identified on SWI using the Microbleed Anatomical Rating Scale
(MARS) (Gregoire et al., 2009). Following the recommendations
made by Greenberg et al. (2009), microbleeds were defined
as areas of round/ovoid black signals, excluding tubular or
linear structures (Greenberg et al., 2009). Suspected microbleeds
were cross-validated on T1- and T2-weighted scans to exclude
microbleed “mimics.” In instances of uncertainty, microbleeds
were labeled as “possible microbleeds” – this includes situations
whereby microbleeds cannot be distinguished from vascular
flow voids. Such cases of “possible microbleeds” were excluded
from analysis, and only “definite microbleeds” were analyzed.
Three participants did not undergo SWI scans and therefore
did not have data on microbleeds. Lacunes were identified using
T1-weighted, T2-weighted, and FLAIR images, following the
STandards for ReportIng Vascular changes on nEuroimaging
(STRIVE) guidelines (Wardlaw et al., 2013a,b). Size thresholds
for lacune classifications were set at a minimum of 3 mm in
diameter (to avoid misclassifications of EPVS as lacunes), and a
maximum of 15 mm (to exclude lesions resulting from non-SVD
etiologies). Lacunes and microbleeds were classified according to
location as deep (e.g., BG, thalamus, internal capsule) or lobar
(e.g., CSO) lesions.
Quantitative Measurements
White matter hyperintensity volumes were obtained using an
automated script on the Statistical Parametric Mapping 8 (SPM8)
suite4; details on the procedures involved have been described
previously (Firbank et al., 2003; Smart et al., 2011). Briefly, SPM8
was used to perform segmentation of T1-weighted images into
GM, WM, and CSF, based on prior probability maps. Using
the GM and WM maps, a brain mask was created and used to
perform removal of non-brain matter from the FLAIR images.
WMH maps were obtained using threshold-based segmentation
at a threshold of 1.40 times the modal pixel intensity, i.e., lesions
with pixel intensity more than 1.40 times the modal intensity
were included in the WMH map. WMH were segmented into
4http://www.fil.ion.ucl.ac.uk/spm/
PVH and DWMH, and regionally by lobar regions (frontal,
parietal, occipital, temporal) as previously described (Firbank
et al., 2003). All generated segmentations were manually reviewed
by experts (NN, AL, and EM) and compared against raw FLAIR
images to identify misclassifications. Misclassifications were
manually corrected, and consensus was met among observers in
cases of uncertainty. Sixteen participants did not have data on
WMH volumes due to missing volumetric FLAIR images or failed
quality assessment, and were excluded from analyses involving
WMH volumes. Total SVD burden was computed using a point-
based system based on the presence or absence of each of the four
SVD markers, according to cut-offs defined by Staals et al. (2014).
White matter hyperintensities, GM, and WM volumes were
normalized by TIV to account for individual differences in
head size. As WMH volumes were right-skewed, square-root
transformations were performed on normalized WMH volumes.
Variables Included in Analyses
For each individual, PSMD value, GM volume, WM volume,
mean MD, TIV, SVD, and cognitive data were available. Regional
data for each SVD marker were as such – (1) WMH: PVH and
DWMH, (2) EPVS: CSO, BG, and midbrain, (3) microbleeds:
deep and lobar, and (4) lacunes: deep and lobar. Global
measures of each SVD type were defined as: (1) total WMH
volume normalized for TIV, (2) EPVS-BG, (3) total number of
microbleeds, (4) total number of lacunes, and (5) total SVD
burden score (Staals et al., 2014). Lacking an established whole-
brain measure of EPVS, EPVS-BG were selected to represent
“global” EPVS, given its relevance in vascular pathology such as
hypertensive arteriopathy and WMH, as opposed to EPVS-CSO
which are more commonly linked to cerebral amyloid angiopathy
(CAA) (Charidimou et al., 2017). Measures of cognition were
MMSE and ACE-R scores. Covariates were gender, age, diagnosis
(healthy control, mild cognitive impairment, Alzheimer’s disease,
progressive supranuclear palsy, dementia with Lewy bodies, and
frontotemporal dementia) and head motion during scanning.
Statistical Analysis
Statistical analysis was performed using R and SPSS V.21.0.
Normality of continuous data was tested using the Shapiro–Wilk
test. Parametric data were analyzed using either independent
t-tests or analysis of variance (ANOVA), while non-parametric
data were analyzed using the Wilcoxon rank-sum test or Kruskal–
Wallis test. Chi-square tests of independence were used for group
comparisons of categorical variables. Robust linear regression
modeling was performed to examine associations between PSMD,
SVD, and cognition (i.e., ACE-R score). Dominance analysis
was conducted to assess the relative importance of variables in
explaining an outcome. Dominance analysis improves on earlier
methods of assessing relative importance (e.g., standardized
regression coefficients, squared beta weights, squared zero order
correlations) due to its ability to account for correlations between
predictors in multivariate analysis (Johnson and Lebreton, 2004).
This is an important feature for the purposes of our study, given
the close associations between various brain measures.
The specific statistical tests conducted for each analyses
are as follows: Robust correlation analysis was conducted to
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assess the influence of head motion on PSMD and MD.
Fisher’s r-to-z transformation was used to statistically test
the difference between correlation coefficients. Robust linear
regression modeling was performed to examine associations
between PSMD and individual SVD markers (global and
regional). For each SVD marker, two models were estimated.
The first model adjusted only for head motion, while the second
model adjusted for head motion, gender, age, and diagnostic
group. The relative contributions of each global SVD marker to
PSMD were examined using dominance analysis. Associations
between regional PSMD and regional WMH volumes were
analyzed using robust correlational analysis. Relative weights
analysis and dominance analysis were conducted in R to test the
significance of regional differences in each SVD type (e.g., lobar
microbleeds vs. deep microbleeds), and the relative importance
of PSMD and SVD markers to ACE-R score. Dominance analysis
was also conducted to compare the relative contribution of
WMH, GM, and WM volumes to PSMD. Diagnostic group and
ACE-R scores were further added in the model as covariates
to control for the cause and degree of cognitive impairment.
Receiver operating characteristic (ROC) curve analysis was
conducted to examine the ability of PSMD and SVD markers
to distinguish cognitively impaired from cognitively healthy
participants. Area under the curve (AUC) of ROC curves
were compared using Delong’s test. To correct for multiple
comparisons, Holm–Bonferroni corrections were conducted.
Statistical significance was set at p< 0.05.
RESULTS
Sample characteristics, cognitive scores, and brain imaging
features are presented in Table 1. The sample was majority
male (60.7%), had a mean age of 70.6 years (SD 7.8), and
an average of 13.3 years of education (SD 2.9). Participants
had a mean MMSE score of 26.4 and mean ACE-R score of
79.4. In terms of cerebrovascular burden, 37% had significant
WMH, defined as PVH extending into the deep WM (Fazekas 3)
and/or confluent or early confluent DWMH (Fazekas 2–3). 45%
displayed moderate to severe EPVS in the BG, 35% possessed one
or more lacune, and 35% had at least one microbleed. The sample
had a mean total SVD burden score (Staals et al., 2014) of 1.50
(out of 4), with 19% scoring a 3 or 4.
In robust correlation analysis, PSMD values were significantly
influenced by the degree of head motion during scanning
(r = 0.265, p = 0.001), highlighting the importance of adjusting
for head motion in analyses involving PSMD. Mean MD was also
influenced by head motion (r = 0.186, p = 0.026). Fisher’s r-to-z
transformation showed that the extent to which PSMD and MD
were influenced by head motion were not statistically different
(z =−1.19, p = 0.233).
Global Associations Between PSMD and
SVD Markers
Robust linear regression models were used to examine
associations between PSMD and SVD markers in separate
models for each marker. Controlling only for head motion,
TABLE 1 | Participant characteristics.
n 145
Demographics
Sex, % female 39.3
Age (years) 70.6 (7.8)
Education (years) 13.3 (2.9)
Cognition
MMSE 26.4 (3.8)
ACE-R 79.4 (15.0)
Vascular risk
Hypertension (%) 25.8
Hyperlipidemia (%) 27.5
Diabetes Mellitus (%) 6.1
Current smoker (%) 6.4
MRI features
GM volume1 39.0 (2.9)
WM volume1 32.3 (2.7)
Mean MD 0.77 (0.04)
Mean FA 0.49 (0.03)
WMH (Fazekas scale; 0–3) 1.83 (0.83)
WMH (volume)1 0.69 (0.71)
EPVS (basal ganglia; 0–4) 1.51 (0.63)
Microbleeds (count) 1.44 (6.3)
Lacunes (count) 0.86 (2.7)
Total SVD burden score (0–4) 1.50 (1.12)
PSMD 5.51e−4 (1.03e−4)
Data are presented as mean (standard deviation), with exception of gender.
1Normalized volume adjusting for total intracranial volume. Only n = 129 had data
on WMH volume, and n = 142 had data on microbleeds, n = 132 had data on
hypertension, n = 131 had data on hyperlipidemia and diabetes, n = 140 had data
on smoking. GM, gray matter; WM, white matter; MD, mean diffusivity; WMH, white
matter hyperintensities; EPVS, enlarged perivascular spaces; SVD, small vessel
disease; PSMD, peak width of skeletonized mean diffusivity.
almost all global and regional SVD markers and total SVD
burden score were significantly associated with PSMD (t = 3.03–
8.02, p ≤ 0.001–0.003), with exception of midbrain EPVS and
deep lacunes (Table 2). Accounting for multiple comparisons
using Holm–Bonferroni correction, WMH, microbleeds, EPVS
in the CSO and BG, lobar lacunes, overall lacune load, and
total SVD burden score remained significantly associated
with PSMD. However, upon controlling for gender, age, and
diagnosis, in addition to head motion, only associations with
WMH, microbleeds, and lobar lacunes remained significant
(t = 2.14–5.08, p ≤ 0.001–0.038) (Table 2).
Relative Contribution of SVD Markers to
PSMD
Dominance analysis demonstrated that WMH volume
(RW = 0.19, DW = 0.14) outperformed EPVS (RW = 0.04,
DW = 0.003), microbleeds (RW = 0.05, DW = 0.02), and
lacunes (RW = 0.02, DW = 0.01) in predicting PSMD. EPVS
and microbleeds were comparable in dominance, although
both outperformed lacunes in predicting PSMD. The same
findings were observed when WMH volume was replaced by
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TABLE 2 | Association between PSMD and markers of SVD using robust linear regression.
Model 1 Model 2
t p t P
WMH (Fazekas score)
Periventricular 5.67 <0.001***† 3.92 <0.001***†
Deep 3.79 <0.001***† 2.14 0.038*
Overall 5.73 <0.001***† 3.87 <0.001***†
WMH volume
Periventricular 7.70 <0.001***† 4.71 <0.001***†
Deep 5.49 <0.001***† 2.99 0.007**
Overall 8.02 <0.001***† 5.08 <0.001***†
EPVS
Centrum semiovale 3.09 0.002**† 0.71 0.476
Basal ganglia 3.41 <0.001***† 1.46 0.147
Midbrain 0.30 0.761 −1.56 0.114
Microbleeds (count)
Lobar 4.15 <0.001***† 4.85 <0.001***†
Deep 3.58 <0.001***† 4.10 <0.001***†
Total number 4.14 <0.001***† 4.84 <0.001***†
Lacunes (count)
Lobar 3.22 0.001**† 3.78 <0.001***†
Deep −0.59 0.555 −1.68 0.086
Total number 3.03 0.002**† −1.87 0.371
Total SVD burden score 3.11 0.003**† 0.56 0.581
Model 1 adjusts for head motion only, Model 2 adjusts for head motion, age, gender, and diagnosis. Bold p-values signify statistical significance. *p < 0.05, **p < 0.01,
***p < 0.001. †Statistically significant after correcting for multiple comparisons using Holm–Bonferroni correction.
the semi-quantitative measure of WMH using the Fazekas scale
(RW = 0.14, DW = 0.10).
Regional Contribution to PSMD
Within each SVD marker, we examine the relative contribution
of regional burden to PSMD using dominance analysis and
relative weight analysis. For WMH, dominance analysis showed
that PVH was a stronger predictor of PSMD, compared to
DWMH – this was true for both semi-quantitative (Fazekas)
and quantitative (volume) measurements of WMH (Table 3).
Using Fazekas ratings, PVH contributed 66.4%, while DWMH
accounted for 33.6% of R2 in the model, and 71.7 and 28.3%,
respectively, for volumetric WMH measurements. EPVS-BG
and EPVS-CSO were comparable in their contribution to
PSMD (60.3 and 38.8%, respectively), although both regions
were more predictive than midbrain EPVS (0.9%). Microbleeds
and lacunes in lobar regions (58.0 and 85.1%, respectively)
contributed significantly more to the PSMD score, compared
to the same lesions in deep brain regions (42.0 and 14.9%,
respectively; Table 3).
Comparing the Contribution of SVD and
Neurodegeneration to PSMD
To assess the relative contribution of cerebrovascular damage
and general neurodegeneration in predicting PSMD score,
we performed multiple linear regression analysis, relative
weight analysis, and dominance analysis to comparing the
relative importance of WMH volume, GM volume, and WM
volume to PSMD. PSMD was associated with WMH volume
(β = 0.492, p < 0.001), but not GM volume (β = −0.149,
p = 0.181) or WM volume (β = −0.178, p = 0.111) in
multiple regression analysis. Dominance analysis and relative
weight analysis demonstrated that WMH burden contributed
significantly more to PSMD score (RW = 0.25, DW = 0.24),
compared to GM (RW = 0.06, DW = 0.01) and WM (RW = 0.06,
DW = 0.11) volume. To account for different causes and severity
of cognitive impairment, a second model was estimated whereby
diagnostic group and ACE-R scores were further added into the
equation. Similar findings were obtained from this second model,
whereby WMH volume was the strongest contributor to PSMD
(β = 4.03, p< 0.001).
Region-Specific Associations
To examine whether regional PSMD scores corresponded with
SVD burden in the same area, robust correlation analysis
was conducted (Figure 2). All regional PSMD values were
significantly associated with WMH volume across regions
even after correcting for multiple comparisons using Holm–
Bonferroni correction (r = 0.25–0.61, p ≤ 0.001–0.005)
(Figure 2). Although significant, Fisher’s r-to-z transformations
indicated that WMH was generally less correlated to temporal
lobe PSMD (r = 0.25–0.39, p ≤ 0.001–0.004), while PSMD
was generally less closely related to WMH in the occipital lobe
(r = 0.25–0.44, p ≤ 0.001–0.005). Aside from these regions
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TABLE 3 | Relative weight analysis and dominance analysis comparing regions within each SVD marker.
β p Relative weight % contribution to R2 Dominance weight
WMH (Fazekas)
Periventricular 0.339 < 0.001* 0.126 66.4 0.075a
Deep 0.140 0.135 0.064 33.6 0.013
WMH (volume)
Periventricular 0.503 < 0.001* 0.193 71.7 0.117a
Deep 0.022 0.844 0.077 28.3 < 0.001
EPVS
Centrum semiovale 0.179 0.038* 0.044 38.8 0.027b
Basal ganglia 0.243 0.005* 0.070 60.3 0.052b
Midbrain −0.048 0.558 < 0.001 0.9 0.002
Microbleeds
Lobar 0.225 0.107 0.053 58.0 0.017c
Deep 0.089 0.523 0.038 42.0 0.003
Lacunes
Lobar 0.241 0.004* 0.054 85.1 0.057d
Deep −0.114 0.168 0.009 14.9 0.013
*Significantly associated with PSMD (p < 0.05). a In dominance analysis, periventricular WMH dominated deep WMH in contribution to PSMD. b In dominance analysis,
EPVS in the centrum semiovale and basal ganglia dominated midbrain EPVS in contribution to PSMD. c In dominance analysis, lobar microbleeds dominated deep
microbleeds in contribution to PSMD. d In dominance analysis, lobar lacunes dominated deep lacunes in contribution to PSMD.
FIGURE 2 | Robust correlation matrix depicting regional associations between PSMD and WMH volumes. Values represent robust correlation coefficients.
with weaker correlations, it was notable that associations were
not significantly higher in corresponding areas (e.g., left frontal
PSMD and left frontal WMH; r = 0.31–0.59, p< 0.001) compared
to non-corresponding areas (e.g., left frontal PSMD and right
temporal WMH; r = 0.25–0.61, p ≤ 0.001–0.005).
PSMD and Cognition
We investigated associations between PSMD and global measures
of cognition using robust linear regression analysis, adjusting
for gender, age, and head motion. Higher PSMD was related
to lower ACE-R (t = −4.07, p < 0.001) and MMSE scores
(t = −2.13, p = 0.033). Dominance analysis indicated that
PSMD contributed the most to ACE-R score (RW = 0.119,
DW = 0.098), outperforming all SVD markers (RW = 0.004–
0.035, DW ≤ 0.001–0.015) (Table 4).
Receiver operating characteristic analysis was conducted to
evaluate the ability of PSMD to discriminate between participants
with and without cognitive impairment, as defined by an ACE-R
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TABLE 4 | Dominance analysis to compare relative importance of PSMD and SVD markers in predicting cognition (ACE-R).
β p Relative weight % contribution to R2 Dominance weight
PSMD −0.373 <0.001* 0.119 68.1 0.098*
WMH (volume) −0.163 0.138 0.035 21.8 0.015
EPVS (basal ganglia) 0.164 0.083 0.011 3.5 <0.001
Microbleeds (count) 0.100 0.490 0.004 3.4 <0.001
Lacunes (count) 0.050 0.360 0.004 3.1 <0.001
PSMD (bold) dominated all other variables in predicting ACE-R score; *statistical significance at p < 0.001.
FIGURE 3 | Receiver operating characteristics (ROC) curves separating cognitively impaired from cognitively healthy participants.
cut-off of 83 (Figure 3). PSMD performed moderately well at
detecting cognitive impairment (AUC = 77%, 95% CI = 69–85%).
AUC derived from ROC curves were compared against PSMD
using Delong’s test. AUC of PSMD was significantly greater than
the curves of all SVD markers (AUC = 0.48–0.63), including
volumetric measurements of WMH (p = 0.014), which derived
the largest AUC (AUC = 63%, 95% CI = 54–73%) among all SVD
markers. The AUCs of semi-quantitative SVD measures ranged
from 48 to 59%, which were all significantly smaller than the
PSMD (p < 0.01). The ROC curves of global brain measures
were also assessed. Delong’s tests indicated that PSMD performed
similarly to GM volume (p = 0.901), WM volume (p = 0.146),
and MD standard deviation (p = 0.264) in detecting cognitive
impairment, but outperformed FA measures (p = 0.010–0.025)
and mean MD (p = 0.004) (Figure 3).
DISCUSSION
This study demonstrated robust associations between PSMD
and the four core markers of SVD, both globally and
regionally. PSMD appeared to be driven by these markers
of vascular pathology, more so than markers of generalized
neurodegeneration (GM and WM atrophy). Regional analysis
showed that PSMD was associated with WMH across the
entire brain, and that regional PSMD was not more closely
related to WMH in corresponding regions, supporting the
notion that PSMD is a measure of diffuse pathology. In
comparison to traditional SVD markers, PSMD was more
strongly associated with cognition, and performed better at
detecting cognitive impairment, although it performed similarly
to global brain measures.
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Expanding on existing research, which has mostly examined
PSMD in relation to WMH (Baykara et al., 2016; Deary et al.,
2019), this present study demonstrated that associations with
PSMD were not confined to WMH, but extended to other key
SVD markers of EPVS, lacunes, and microbleeds, and total SVD
burden. Nearly all global and regional measurements of SVD
were associated with PSMD, with exception of deep lacunes and
EPVS in the midbrain (Table 2). In terms of relative contribution,
WMH was the strongest predictor of PSMD compared to
other SVD markers.
Within each SVD marker, regional burden was compared
for their relative contribution to PSMD. In terms of WMH,
PSMD was more closely related to PVH than DMWH, a
pattern characteristic of hypertensive arteriopathy. This suggests
that PSMD may be more strongly affected by underlying
vascular pathology affecting deep structures, rather than
observable parenchymal alterations of DWMH. In line with
DTI parameters in general, this demonstrates the ability of
PSMD to detect microstructural changes in normal appearing
WM that are not yet visible on conventional MRI (Van
Norden et al., 2012). EPVS-CSO and EPVS-BG performed
similarly well in predicting PSMD, although both contributed
more to PSMD than EPVS-MB. Finally, focal cerebrovascular
lesions in the form of lacunes and microbleeds were more
strongly associated with PSMD when they occurred in lobar
(as opposed to deep) regions. Taken together, PSMD appears
to be sensitive to both (1) early microstructural tissue
damage of vascular pathology, and (2) diffuse distribution of
cerebrovascular lesions, positioning it as a valuable marker of
overall SVD burden.
White matter hyperintensities outperformed global measures
of brain volume as a predictor of PSMD, supporting earlier
findings that PSMD was associated with SVD but not
neurodegeneration (Baykara et al., 2016). The exclusivity of
this relationship is an important feature that supports the
use of PSMD as a valid and specific marker of SVD. Baykara
et al. (2016) arrived at the same conclusion through their
observation that PSMD was associated with WMH load,
but did not differ between healthy controls, patients with
mild cognitive impairment and low WMH, and Alzheimer’s
disease patients with low WMH. Building upon this, we
adopted a different approach by comparing WMH volume
directly with volumetric measures of brain atrophy in
relation to PSMD. Encouragingly, our findings supported
the argument that PSMD was specific to vascular pathology,
and not generalized neurodegeneration. However, given the
heterogeneous etiologies of WMH, it is possible that associations
between WMH and PSMD may reflect a combination of
vascular and non-vascular pathologies (Habes et al., 2018;
Alber et al., 2019).
Regional associations between PSMD and WMH supported
the notion of PSMD as a diffuse marker of overall cerebrovascular
burden. Results demonstrated that PSMD, regardless of location,
was associated with WMH load across all regions. Importantly,
associations between PSMD and WMH were not significantly
stronger in corresponding regions (e.g., left frontal PSMD
and left frontal WMH) compared to non-corresponding
regions, supporting the PSMD’s position as a measure of
diffuse pathology.
Finally, significant associations were found between PSMD
and cognitive performance, independent of gender, age,
diagnosis, and head motion during scanning. This was in line
with existing PSMD research (Baykara et al., 2016; Deary et al.,
2019; Vinciguerra et al., 2019; Wei et al., 2019). Importantly,
PSMD was found to be a stronger predictor of cognitive
performance than conventional markers of SVD. This was
further supported by ROC analysis which demonstrated
the PSMD’s ability to distinguish cognitively impaired from
cognitively healthy participants with greater accuracy than
traditional markers of SVD. The lack of association with SVD
markers like lacunes and microbleeds may stem from a lack of
statistical power, given the low incidence of such lesions. On
the other hand, PSMD performed similarly to GM and WM
volumes. This is perhaps unsurprising, given that majority of
participants were patients with cognitive impairment/dementia
wherein structural atrophy is a key characteristic. We also
compared PSMD to conventional measures of DTI, to determine
if positive PSMD findings were a simple reflection of the general
superiority of DTI measures. We found that PSMD was better
than mean FA and MD values at detecting cognitive impairment,
although it was comparable to the standard deviation of MD
in the brain. In contrast to global brain measures, PSMD may
be able to detect cognitive deficits stemming from vascular
pathology. Unfortunately, the cognitive tests used in this study
were global measures of cognition, which are less sensitive to
SVD-related changes compared to tests of executive function
and information processing speed – using such measures may
produce even stronger associations.
A key strength of this study was the inclusion of all four
major MRI markers of SVD, and region-specific SVD measures.
Furthermore, this study included both (1) semi-quantitative
visual rating of WMH, which are more applicable to clinical
settings, and (2) quantitative volumetric measurements of WMH,
which are more sensitive and reliable at detecting WM changes.
However, this study was limited by a number of factors. Firstly,
the study sample comprised a heterogeneous mix of dementia
diagnoses. This heterogeneity may reduce power to detect
differences and emphasizes commonalities in the associations
across diagnostic groups. However, it should not prevent
investigations on the sensitivity of PSMD and its relationship
to other measures. Furthermore, this transdiagnostic approach
allowed us to determine whether results were independent of
diagnostic grouping, which we were able to demonstrate through
the consistency of results even after inclusion of diagnostic group
as a covariate in regression models.
Future research should examine the sensitivity of PSMD to
longitudinal SVD progression, investigate PSMD in relation to
other known correlates of SVD such as vascular risk factors (e.g.,
hypertension) and other brain imaging measures (e.g., cerebral
hypoperfusion, blood–brain barrier permeability), and assess its
association to specific cognitive domains (e.g., executive function,
processing speed). However, given the sensitivity of PSMD to
head motion during scans, this should be controlled for in all
intended use of the PSMD score.
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CONCLUSION
This present study demonstrates the PSMD’s sensitivity to
vascular pathology instead of just non-specific neurodegene-
ration, and PSMD’s ability to detect microstructural vascular
damage that is not visible on conventional MRI. Furthermore,
PSMD appeared to be a diffuse marker of overall SVD burden,
capturing different types of cerebrovascular alterations across the
whole brain. This marker was also clinically relevant in terms
of detecting cognitive impairment, and surpassed conventional
MRI markers of SVD and DTI measures. Given the convenience
of its fully automated, publicly available computation method,
the PSMD is well-positioned as a promising new marker of SVD
which can be easily implemented in large samples.
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